# Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

Study · id `cardio:ct-nct07434661` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07434661](<https://clinicaltrials.gov/study/NCT07434661>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07434661

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07434661. Randomized; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07434661, source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07434661, source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT07434661, source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)
- Completion: 2029-01 (anticipated) (ClinicalTrials.gov record NCT07434661, source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT07434661, source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07434661-2026-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
- Acronym: SAFE-HEART
- Condition: Valve Disease, Heart
- Condition: Atrial Fibrillation (AF)
- Condition: Valve Replacement Surgery
- Condition: Aortic Valve Surgery
- Condition: Mitral Valve Annuloplasty
- Condition: Mitral Valve Repair
- Condition: Mitral Valve Surgery
- Intervention (Drug): Apixaban
- Intervention (Drug): Warfarin
- Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Meshalkin Research Institute of Pathology of Circulation (`cardio:org-meshalkin-research-institute-of-pathology-of-circulation`)

## Provenance

Content hash: 5c49c6603fc687a9318ee99b32e6bfba330b0226c80fb9fbd2ff4903f32c047b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
